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Objectives: To study the impact of contact force (CF) sensing on ﬂuoroscopy, procedure, left atrial (LA)
and ablation times and number of ablations during atrial ﬁbrillation (AF) ablation.
Background: Catheter ablation is an effective treatment for symptomatic AF. Recently a new ablation
catheter providing real-time CF has been approved for use.
Methods: A nested case-control study was performed comparing radiofrequency ablation of AF using the
irrigated CF-sensing ThermoCool SmartTouch catheter versus open-irrigated ThermoCool SF catheter
(Biosense Webster, Inc., Diamond Bar, California). Demographic and procedure data were obtained and
student t-test was used to compare data between groups.
Results: Thirty consecutive adult patients were included with 15 patients in each group. Mean ﬂuoros-
copy time was signiﬁcantly lower in CF group (19.4 ± 8 vs 40.7 ± 8 min, p < 0.0001). LA time was
signiﬁcantly lower in CF group (151.7 ± 44 vs 185.7 ± 35 min, p ¼ 0.01). There were no signiﬁcant dif-
ferences in procedure time between CF and SF groups (204 ± 37 vs 207 ± 36 min) and ablation time
(121 ± 32 vs 122 ± 37 min). When patients who only underwent pulmonary vein isolation (PVI) were
compared, ﬂuoroscopy time was signiﬁcantly lower in CF group (18 ± 9 vs 37.8 ± 5 min, p < 0.0001) as
was LA time (141.4 ± 39 vs 171.8 ± 30 min, p ¼ 0.04). Fluoroscopy time was also signiﬁcantly lower in CF
subgroup with additional ablation (20.9 ± 7 vs 44.9 ± 10 min, p < 0.001).
Conclusion: Use of CF-sensing catheter signiﬁcantly reduced ﬂuoroscopy and LA times during AF ablation
with similar acute efﬁcacy.
Copyright © 2016, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The prevalence of atrial ﬁbrillation (AF) in the developed world
is approximately 1.5e2% of the general population and its incidence
is expected to dramatically increase in the future [1]. Catheter
ablation of AF is now recognized as a Class I indication for treat-
ment of symptomatic AF refractory to at least one membrane active
anti-arrhythmic drug [2]. Ablation of AF, while effective, can
sometimes be a time consuming procedure with signiﬁcant ﬂuo-
roscopy exposure for the patient and physician. Until recently, the
surrogate markers for tissue contact during pulmonary vein isola-




ociety. Production and hosting byelectrogram diminution and impedance changes during ablation,
but there was no direct quantitative way to ensure adequate tissue
contact to maximize effective lesion formation. With the develop-
ment of the Biosense Webster Smart touch force sensing ablation
catheter this deﬁciency has been overcome. Good electrode-tissue
contact with objective measurement of contact force (CF) by use of
an irrigated CF-sensing catheter has been demonstrated to be safe
and effective in RF ablation procedures [3]. We conducted this
study to assess the real-world impact of contact-force sensing on
procedure and ﬂuoroscopy times during radiofrequency (RF)
ablation of AF.
2. Methods
The Institutional Review Board at Einstein Medical Center,
Philadelphia, approved the study protocol. This was a retrospective
study that included patients who had undergone RF ablation of AF
at Einstein Medical Center between August 2012 and August 2014.Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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patients who underwent RF ablation of AF with the ThermoCool
SmartTouch catheter were included in the CF group, while the last
15 patients who underwent RF ablation of AF with the ThermoCool
SF Catheter were included in the SF group. Inclusion criteria
included patient age >18 years, at least one documented episode of
symptomatic paroxysmal or persistent AF, non-responsiveness to at
least one anti-arrhythmic drug therapy (Class I, Class III or atrio-
ventricular nodal blocking agents) and previous AF ablation within
the last two years at Einstein Medical Center, Philadelphia.
Demographic and procedural data were obtained from the
electronic database. Procedure time was deﬁned as the time in-
terval in minutes between insertion of the ﬁrst diagnostic catheter
to the removal of the last diagnostic catheter after ablation. Left
atrial time was deﬁned as the time interval in minutes between the
ﬁrst transseptal puncture and removal of the last diagnostic cath-
eter from the left atrium after ablation. Ablation time was deﬁned
as the summed duration of the individual ablation times in
minutes.
2.1. CF sensing Catheter/CF sensing technology
The ThermoCool SmartTouch catheter (Biosense Webster, Inc.,
Diamond Bar, California) is a 7.5 Fr CF sensing catheter and has a
3.5 mm tip electrode with 6 small holes (0.4 mm diameter) around
the circumference for saline irrigation. The catheter tip electrode is
mounted on a precision spring, which permits micro-deﬂection,
which is measured by three magnetic sensors located proximal to
the spring. The system calculates the associated magnitude and
angle of CF based on the micro-deﬂection, which is displayed both
continuously and as the average value (over 1 s) on an electro-
anatomical mapping system (CARTOXP, BiosenseWebster, Inc.) [4].
The ThermoCool SF Catheter (Biosense Webster, Inc) is a non-CF
sensing, open irrigation catheter with an 8 Fr tip electrode, 3.5 mm
in length with 56 very small holes (diameter 0.003500) positioned
around the entire electrode. It contains an embedded thermo-
couple for monitoring electrode temperature during RF ablation.
2.2. AF ablation procedure
All procedures were performed under general anesthesia with
mechanical ventilation. A decapolar catheter was inserted trans-
venously and positioned in the coronary sinus. Intracardiac echo-
cardiography was performed using a 9 Fr linear phased array
ultrasound catheter (AcuNav, Biosense Webster Inc., Diamond Bar,
CA), which was advanced into the right atrium to guide the trans-
septal procedure, (puncture) monitor ablation catheter position
and development of any pericardial effusion during the procedure.
Double trans-septal procedure (puncture) was performed after
intravenous heparin bolus administration to maintain activated
clotting time >350 s. Two long 8.5 Fr sheaths (Agilis, St Jude
Medical, Inc. and SL1, St JudeMedical, Inc.) were introduced into the
left atrium (LA). Electroanatomic shell of the LA and the pulmonary
veins (PV) was created using a PentaRay NAV catheter (Biosense
Webster Inc., Diamond Bar, CA) and a magnetic-based electro-
anatomic mapping system (CARTO System, Biosense Webster Inc.,
Diamond Bar, CA). A circular electrode catheter (Lasso, Biosense
Webster, Inc.) was inserted into the LA for recording pulmonary
vein (PV) potentials. The ThermoCool SmartTouch or ThermoCool
SF mapping/ablation catheter was inserted through the second
trans-septal sheath. To calibrate the CF sensor to 0 g (baseline non-
contact value), the CF-sensing catheter was positioned centrally in
the LA chamber without endocardial contact, conﬁrmed by ﬂuo-
roscopy and intracardiac echocardiography. Pulmonary vein
antrum isolation by a circumferential lesion set was performed inall 30 patients with conﬁrmation of entrance and exit block. The
peak contact force in the ThermoCool SmartTouch group did not
exceed 40 g, and a minimum contact force of 5e10 g was targeted.
Additional ablation was performed at the operator’s discretion. It
included ablation of complex fractionated atrial electrograms, LA
linear ablation lesions and cavotricuspid isthmus ablation in cases
of inducible atrial ﬂutter. Isoproterenol infusion was used post-
ablation to identify dormant foci.3. Statistical analysis
Data are reported as mean ± SD for continuous variables and as
number and percentage for categorical variables. Student t-test was
used to compare continuous variables and the chi-square test was
used to compare categorical variables. A 2-tailed p-value <0.05 was
considered signiﬁcant in advance.4. Results
Thirty consecutive patients were included, 15 patients had AF
ablation using ThermoCool SmartTouch catheter and 15 had AF
ablation using ThermoCool SF catheter. Baseline characteristics of
the two groups are described in Table 1.
Six subjects in the ThermoCool SmartTouch group underwent
PVI alone. Nine patients underwent additional ablation: 5 had
additional focal non-PV ablation targeting complex fractioned
electrograms while the remaining 4 underwent focal and linear
ablation. Eight subjects in the ThermoCool SF group underwent PVI
alone. Two patients underwent additional focal non-PV ablation
targeting complex fractioned electrograms, while 5 underwent
additional focal and linear non-PV ablation. Acute success
described as achievement of entrance and exit block at all pulmo-
nary veins and maintenance of sinus rhythm was achieved in all
patients in both groups. There were no acute post-procedural
complications in both groups.
A comparison between the mean procedure, ﬂuoroscopy, abla-
tion and left atrial times and the average number of ablations in the
ThermoCool SmartTouch versus the ThermoCool SF group is pre-
sented in Table 2. Mean ﬂuoroscopy time (19.4 ± 8 vs 40.7 ± 8 min)
and left atrial time (151.7 ± 44 vs 185.7 ± 35min) were signiﬁcantly
lower in the ThermoCool SmartTouch group. There were no sig-
niﬁcant differences in procedure time and ablation time between
the two groups: procedure times; (ThermoCool SmartTouch
204 ± 37 min vs ThermoCool SF 207 ± 37 min); ablation times
(ThermoCool SmartTouch 121 ± 32 min vs ThermoCool SF
122 ± 37 min).
A comparison between the mean procedure, ﬂuoroscopy, abla-
tion and left atrial times and the average number of ablations in the
subsets of patients who underwent PVI alone and those who un-
derwent PVI plus additional ablation is presented in Table 3.
There was signiﬁcant ﬂuoroscopy time reduction noted early on
within the ﬁrst ﬁve cases with CF sensing catheter as compared to
non-CF sensing group (ThermoCool SmartTouch ﬁrst 5
27.64 ± 6.3 min vs ThermoCool SF 40.7 ± 8 min) (Table 4). Also,
ﬂuoroscopy time was signiﬁcantly lower in the last ﬁve patients
compared to the ﬁrst ﬁve patients in the CF-sensing group (Ther-
moCool Smart Touch last 5e14.96 ± 7.8 min vs ThermoCool Smart
Touch ﬁrst 5e27.64 ± 6.3 min) (Table 5).
When AF patients who only underwent PVI were compared,
ﬂuoroscopy time and left atrial time were signiﬁcantly lower in the
ThermoCool SmartTouch group (Fig. 1, Fig. 2). Fluoroscopy timewas
also signiﬁcantly lower in the ThermoCool SmartTouch subgroup
with additional focal or linear ablation (Fig. 1).
Table 1
Demographics.
Parameters ThermoCool SmartTouch group (n ¼ 15) ThermoCool SF group (n ¼ 15)
Age (years) 60 ± 10 61 ± 5
Male (%) 73 60
Hypertension (%) 93 87
Dyslipidemia (%) 47 53
Diabetes mellitus (%) 20 13
Coronary artery disease (%) 27 13
Valvular disease (%) 7 7
Secondary arrhythmias (%) 33 33
Left ventricular ejection fraction (%) 54.6 ± 9.9 53 ± 10.8
LA diameter (cm) 4.4 ± 0.6 4.5 ± 0.6
Table 2
Mean procedure, ﬂuoroscopy, ablation and left atrial times and number of ablations.
Parameter ThermoCool SmartTouch ThermoCool SF p value
Procedure time (mins) 203.8 ± 37 206.7 ± 37 0.4
Fluoroscopy time (mins) 19.4 ± 8 40.7 ± 8 <0.0001
Ablation time (mins) 120.6 ± 32 122.3 ± 37 0.4
No. of ablations 100 ± 14 97 ± 24 0.33
Left atrial time (mins) 151.7 ± 44 185.7 ± 35 0.01
Table 3
Comparison between the subsets of patients who underwent PVI alone and those who underwent additional ablation.
Parameter ThermalCool SmartTouch ThermaCool SF p value
PVI Procedure time (mins) 194.5 ± 21 192.9 ± 35 0.4
Fluoroscopy time (mins) 18.0 ± 9 37.8 ± 5 <0.01
Ablation time (mins) 111.0 ± 22 104.0 ± 12 0.21
No. of ablations 98 ± 17 85 ± 13 0.05
Left atrial time (mins) 141.4 ± 39 171.8 ± 30 0.04
PVI þ CFAE Procedure time (mins) 214.6 ± 50 227.3 ± 30 0.2
Fluoroscopy time (mins) 20.9 ± 7 44.9 ± 10 <0.01
Ablation time (mins) 131.6 ± 40 149.5 ± 45 0.2
No. of ablations 102 ± 10 114 ± 28 0.3
Left atrial time (mins) 163.4 ± 49 206.7 ± 34 0.05
Table 4
Comparison between all ThermoCool SF cases with the ﬁrst ﬁve ThermoCool SmartTouch cases.
Parameters ThermoCool SF ThermoCool SmartTouch ﬁrst ﬁve cases p value
Fluoro time 40.7 ± 8 27.64 ± 6.3 0.005
Procedure time 206.7 ± 37 215.8 ± 44.2 0.692
Ablation time 122.3 ± 37 134.4 ± 40.2 0.573
LA time 185.7 ± 35 165.8 ± 20.7 0.148
Table 5
Comparison between the ﬁrst ﬁve and last ﬁve cases in the ThermoCool SmartTouch
group.
ThermoCool SmartTouch First 5 cases Last 5 cases p value
Fluoro time 27.64 ± 6.3 14.96 ± 7.8 0.02
Procedure time 215.8 ± 44.2 202.6 ± 47.6 0.66
Ablation time 134.4 ± 40.2 114.8 ± 35.8 0.44
LA time 165.8 ± 20.7 163.4 ± 59.7 0.94
Fig. 1. Fluoroscopy time (minutes).
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Use of CF-sensing catheter has been proven to be safe and
effective in RF ablation of AF. However, its real-world impact on
ﬂuoroscopy time and procedure time during AF ablation is largely
unknown. Our study has demonstrated a signiﬁcant reduction in
mean ﬂuoroscopy time with the use of a CF-sensing catheter. This
reduction in ﬂuoroscopy time was seen in patients who underwentPVI alone as well as patients who underwent additional focal or
linear non-PV ablation. There was also a signiﬁcant overall decrease
in the left atrial time with the use of CF-sensing catheter. There was
no signiﬁcant reduction in the procedure time, ablation time or the
number of ablation lesions with use of CF sensing.
The single-procedure efﬁcacy rate of catheter ablation of drug-
refactory paroxysmal AF is 60e80% twelve months after the pro-
cedure. The current incidence of major complications after catheterablation for atrial ﬁbrillation is between 1% and 5%. Much effort has
been invested in the last ﬁfteen years in improving efﬁcacy but the
Fig. 2. Left atrial time (minutes).
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force used during ablation has the potential advantage of increasing
efﬁcacy by reducing late PV reconnection, streamlining the ablation
procedure and minimizing some of these complications.
It has been shown in prior studies that contact-force is a major
determinant of lesion size. An open-irrigated contact-force sensing
catheter helps in selection of optimum RF power and application
time to minimize the risk of steam pop and thrombus while
increasing lesion size thereby ensuring effective PV isolation [5,6]
The SMART-AF study demonstrated that ablation with the Ther-
moCool CF-sensing catheter was safe and effective for the treat-
ment of drug refractory symptomatic PAF [3]. Another study using a
different CF-sensing catheter system demonstrated that contact
force during catheter ablation for AF correlated with better clinical
outcomes [7].
A longer catheter dwell time in the left atrium exposes patients
to thrombus or char formation on ablation apparatus, air entry with
an inevitable variability in the degree of anticoagulation during the
procedure [8]. We demonstrated a signiﬁcant decrease in the
catheter dwell time in the left atrium in the ThermoCool Smart-
Touch group which could potentially lead to a reduction in com-
plications related to atrial ﬁbrillation ablation.
Radiation exposure is an often underappreciated complication
of catheter ablation procedures. X-ray exposure is associated with
stochastic (cancer and genetic defects) and deterministic risks (hair
loss, skin burns, cataracts, diminished fertility, bone marrow sup-
pression etc). RF ablation for atrial ﬁbrillation is associated with
signiﬁcant radiation exposure for patients and medical staff due to
the length of the procedure, and patient comorbidity like obesity.
The additional lifetime risk of excess fatal malignancies normalized
to 60 min of ﬂuoroscopy has been reported to be 0.07% for women
and 0.1% for men [9]. Another study has estimated the average
excess of fatal cancers to be 650 per million patients undergoing RF
ablation requiring 1 h of ﬂuoroscopy, and average risk for genetic
defects was determined to be 1 per million births [10]. Use of 3D
electroanatomical mapping systems has demonstrated reduction in
ﬂuoroscopy times [11]. Our study demonstrates further reduction
of ﬂuoroscopy time with use of a contact-force sensing catheter
along with use of a 3D electroanatomical mapping system.
Reduction in ﬂuoroscopy time was evident early on with the
ﬁrst 5 patients with use of CF sensing catheter as compared to use
of non-CF sensing catheter. Further, there was signiﬁcant reduction
in ﬂuoroscopy time in last 5 patients as compared to ﬁrst ﬁve pa-
tients out of a total cohort of 15 patients in the CF-sensing group.
This reﬂects that the learning curve for the use of the CF-sensing
catheter is smooth and operator conﬁdence builds quickly with
less reliance on ﬂuoroscopy during navigation and ablation.The ﬁnding of our study is in agreement with the recent study
by Jarman et al. where they looked at 600 patients undergoing AF
ablation and demonstrated that use of CF sensing catheter was
associated with reduced ﬂuoroscopy time in multivariate analysis
[12]. Zero-ﬂuoroscopy ablation procedures with use of CF sensing
catheter has been shown to be feasible [13]. With evolving tech-
nology, this could be a reality in real world practice for AF ablation
in the future.
6. Study limitations
This was a retrospective single-center study which has inherent
problems with selection bias and confounding by unmeasured
variables. Our sample size was small and we did not have medium
or long-term follow-up results. This may preclude quantiﬁcation of
the presumed risk reduction associated with use of CF catheter. We
opted to enroll subjects in a 1:1 fashion to CF group and SF group.
There were no acute complications noted in our study. This is likely
due to the small sample size and single operator experience.We did
not perform cost analysis comparing the ablation procedures with
two different catheter technologies.
Our study, however, reﬂects real world practice outside of the
clinical trial setting. Our study included both paroxysmal and
persistent AF cases with different ablation strategies. However, all
the procedures done in our study were performed by a single
operator using identical ablation technique. Only acute procedural
outcomewas assessed during the study since medium term follow-
up data was unavailable.
7. Conclusion
In this study, we demonstrated that the use of irrigated CF-
sensing catheter signiﬁcantly reduces ﬂuoroscopy and left atrial
times during AF ablation. Acute success is comparable to stan-
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